YK Bioventures Opportunities GP I, LLC sold $325k of CERO
owner at CERO THERAPEUTICS HOLDINGS, INC.. 3,250,000 shares at an average of $0.10, traded Oct 10, 2024, filed Nov 14, 2024.
Score components
- +12Role10% owner
- +14Trade size$325k at market
- +5Share of holdings soldSold 13% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -69.5%, 3m -90.4%, 6m -96.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-026908, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 10, 2024 | SOpen-market sale Common Stockindirect: By YK Bioventures Opportunities Fund I, L.P. | -3,250,000 | $0.10 | $325k | 22,620,783 | Nov 14, 2024 |
Related signals
Other insiders at CERO THERAPEUTICS HOLDINGS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | CEROsell CERO THERAPEUTICS HOLDINGS, INC. | YK Bioventures Opportunities GP I, LLC owner | $400k 5,957,250 shares | -31% | |
| 33Weak | CEROsell CERO THERAPEUTICS HOLDINGS, INC. | YK Bioventures Opportunities GP I, LLC owner | $383k 3,658,364 shares | -16% | |
| 19Weak | CEROsell CERO THERAPEUTICS HOLDINGS, INC. | Stuart M Sloan owner | $56k 532,486 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.